NCT05226663View on ClinicalTrials.gov

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

August 20, 2026

Study Completion Date

August 20, 2026

Conditions
Breast Carcinoma
Interventions
PROCEDURE

Computed Tomography

Undergo \[18F\]FFT PET/CT

RADIATION

Fluorine F 18 Fluorthanatrace

Given IV

PROCEDURE

Positron Emission Tomography

Undergo \[18F\]FFT PET/CT

Trial Locations (3)

19104

RECRUITING

University of Pennsylvania/Abramson Cancer Center, Philadelphia

63110

RECRUITING

Siteman Cancer Center at Washington University, St Louis

77030

SUSPENDED

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Trevarx Biomedical, Inc

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT05226663 - A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer | Biotech Hunter | Biotech Hunter